The Lancet Oncology最新文献

{"title":"Final phase of HPV vaccination campaign launched in Bangladesh","authors":"Udani Samarasekera","doi":"10.1016/s1470-2045(24)00638-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00638-7","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"242 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142580004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European Commission highlights policies to support return to work for patients with cancer and survivors","authors":"Talha Burki","doi":"10.1016/s1470-2045(24)00637-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00637-5","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"137 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142580003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types","authors":"Karl Semaan, Rashad Nawfal, Elizabeth Nally, Yelena Y Janjigian, Caroline Robert, Solange Peters, Thomas Powles, Toni K Choueiri","doi":"10.1016/s1470-2045(24)00513-8","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00513-8","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Patients receiving subsequent therapy</h2>Initially, we assessed the number of patients in the control groups who underwent any subsequent treatment (including surgery, radiotherapy, or systemic therapy) after a disease-free survival event. Among the 15 perioperative ICI trials examined, only eight trials provided data on the number of patients receiving any subsequent therapy. In the melanoma clinical trials, 62 (89·8%) of 69 patients (CheckMate 76K) and 282 (87·3%) of 323 patients (EORTC 18071) who had a disease-free survival event</section></section><section><section><h2>Patients receiving subsequent systemic therapy</h2>We examined the number of patients who underwent systemic therapy following disease-free survival events in the control group. Among the 15 perioperative ICI trials examined, 13 provided data on the number of patients receiving subsequent systemic therapy. In the melanoma trials, 44 (38·2%) of 115 patients (KEYNOTE-716), 49 (71·0%) of 69 (CheckMate 76K), and 218 (72·2%) of 302 (KEYNOTE-054) who experienced a disease-free survival event received systemic therapy. In the NSCLC trials, 131 (61·8%)</section></section><section><section><h2>Patients receiving subsequent immunotherapy</h2>We then reviewed the proportion of patients receiving subsequent systemic immunotherapy among the patients who experienced a disease-free survival event in the control or non-experimental group. In the melanoma trials KEYNOTE-716 and KEYNOTE-054, which were the only trials with a built-in cross-over, 35 (30·4%) of 115 patients (KEYNOTE-716) and 195 (64·6%) of 302 (KEYNOTE-054) with a disease-free survival event received ICI as subsequent therapy. In the NSCLC trials, 102 (48·1%) of 212 patients</section></section><section><section><h2>Non-immune subsequent systemic therapy</h2>Relapses after surgery in some types of cancers are typically aggressive and surveillance or local therapies are not recommended. An example is urothelial carcinoma, for which regular radiology monitoring within adjuvant trials should enable early detection, necessitating timely intervention.<sup>5</sup> Chemotherapy has been considered the global standard of care for the management of patients with metastatic urothelial carcinoma and is globally available. Therefore, upon relapse, most patients should</section></section><section><section><h2>Real-world scenarios after recurrence</h2>To further understand the vast range of scenarios following tumour relapses, we created a visualisation of real-world instances of reporting subsequent therapies in perioperative trials, specifically focusing on renal cell carcinoma from KEYNOTE-564 (appendix p 3), the only pure adjuvant immunotherapy trial in solid cancers with an overall survival benefit. Our point was to illustrate that analyses of subsequent therapies are time-dependent and complex. For instance, by capturing subsequent</section></section><section><section><h2>Discussion</h2>Only ","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"126 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142579844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Oncol 2024; 25: 1188–201","authors":"","doi":"10.1016/s1470-2045(24)00635-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00635-1","url":null,"abstract":"<em>Karpinski MJ, Hüsing J, Claassen K, et al Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study.</em> Lancet Oncol <em>2024;</em> 25: <em>1188–201</em>—The appendix of this Article has been corrected as of Oct 30, 2024.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"87 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142542089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","authors":"Pier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, Stefan K Barta, Kenji Ishitsuka, Raul Córdoba, Shigeru Kusumoto, Emmanuel Bachy, Kate Cwynarski, Giuseppe Gritti, Anca Prica, Eric Jacobsen, Tatyana Feldman, Yann Guillermin, Daisuke Ennishi, Dok Hyun Yoon, Eva Domingo Domenech, Jasmine Zain, Jie Wang, Jin Seok Kim, Steven M Horwitz","doi":"10.1016/s1470-2045(24)00503-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00503-5","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Peripheral T-cell lymphomas are aggressive non-Hodgkin lymphomas with few treatment options for relapsed or refractory disease. Valemetostat tosylate (valemetostat) is a potent, novel, dual inhibitor of EZH2 and EZH1. We investigated the clinical activity and safety of valemetostat in patients with relapsed or refractory peripheral T-cell lymphoma, and its safety in patients with relapsed or refractory adult T-cell leukaemia/lymphoma.&lt;h3&gt;Methods&lt;/h3&gt;VALENTINE-PTCL01 was a multicentre, open-label, single-arm, phase 2 trial performed at 47 hospitals in 12 countries across Asia, Europe, North America, and Oceania. Patients with either peripheral T-cell lymphoma or adult T-cell leukaemia/lymphoma, aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0–2 received oral valemetostat at 200 mg per day in continuous 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint for patients with peripheral T-cell lymphoma was the CT-based objective response rate by blinded independent central review (BICR) using 2014 Lugano response criteria. Patients who received valemetostat and had a confirmed eligible peripheral T-cell lymphoma subtype on central review were included in the efficacy analysis. The primary endpoint for patients with adult T-cell leukaemia/lymphoma was the safety and tolerability of valemetostat. Safety in both cohorts was assessed in all patients who received at least one dose of valemetostat. The trial is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;NCT04703192&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, and EudraCT, 2020-004954-31, and is closed to enrolment.&lt;h3&gt;Findings&lt;/h3&gt;Between June 16, 2021, and Aug 10, 2022, 133 patients with relapsed or refractory peripheral T-cell lymphoma (median age 69·0 years [IQR 58·0–74·0]; 91 [68%] were male, and 42 [32%] were female) and 22 patients with adult T-cell leukaemia/lymphoma (66·5 years [54·0–73·0]; 15 [68%] were male, and seven [32%] were female) were enrolled. The median follow-up time was 12·3 months (95% CI 11·8–13·8). 52 (44%; 95% CI 35–53) of 119 efficacy-evaluable patients with relapsed or refractory peripheral T-cell lymphoma had an objective response. The most common grade 3−4 adverse events were thrombocytopenia (31 [23%] of 133 patients in the peripheral T-cell lymphoma group and 11 [50%] of 22 patients in the adult T-cell leukaemia/lymphoma group), anaemia (25 [19%] and ten [46%]), and neutropenia (23 [17%] and four [18%]). Serious treatment-emergent adverse events were reported in 53 (40%) patients with peripheral","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142541492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study","authors":"Dai Maruyama, Eric Jacobsen, Pierluigi Porcu, Pamela Allen, Kenji Ishitsuka, Shigeru Kusumoto, Tomoko Narita, Kensei Tobinai, Francine Foss, Kunihiro Tsukasaki, Tatyana Feldman, Yoshitaka Imaizumi, Koji Izutsu, Satoko Morishima, Nobuhiko Yamauchi, Junichiro Yuda, Jonathan E Brammer, Toyotaka Kawamata, Jia Ruan, Kisato Nosaka, Steven M Horwitz","doi":"10.1016/s1470-2045(24)00502-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00502-3","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Few treatment options exist for patients with non-Hodgkin lymphoma, and outcomes remain poor for relapsed or refractory disease. We evaluated the safety and preliminary clinical activity of valemetostat, a novel inhibitor of EZH2 and EZH1, in patients with relapsed or refractory non-Hodgkin lymphomas.&lt;h3&gt;Methods&lt;/h3&gt;This first-in-human, multicentre, open-label, single-arm, phase 1, dose-escalation and dose-expansion trial was done in 19 hospitals across Japan and the USA. Patients were included if they were aged 18 years or older in the USA or 20 years or older in Japan with a primary diagnosis of relapsed or refractory non-Hodgkin lymphoma and an Eastern Cooperative Oncology Group performance status of 0 or 1. In the dose-escalation part, patients received oral valemetostat at doses of 150 mg per day, 200 mg per day, 250 mg per day, and 300 mg per day continuously in 28-day cycles until progressive disease or unacceptable toxicities. All patients received 200 mg per day in the dose-expansion part. The primary endpoints were safety, pharmacokinetics, and the recommended phase 2 dose; the secondary endpoints were the maximum tolerated dose and the antitumour activity of valemetostat. Responses were assessed in patients who received at least one dose, with measurable lesions at baseline according to the International Working Group 2007 revised criteria for malignant lymphoma (peripheral T-cell lymphoma and B-cell non-Hodgkin lymphoma) and the modified 2009 criteria for adult T-cell leukaemia/lymphoma. The trial is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;NCT02732275&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, and is currently active, but not recruiting.&lt;h3&gt;Findings&lt;/h3&gt;Between April 7, 2016, and June 10, 2021, 90 patients (53 [59%] males and 37 [41%] females; 49 [54%] Asian, 33 [37%] White, and eight [9%] Black) were enrolled and treated with valemetostat and included in the safety analysis set. 57 (63%) patients had peripheral T-cell lymphoma, 14 (16%) had adult T-cell leukaemia/lymphoma, and 19 (21%) had B-cell non-Hodgkin lymphoma. Seven (8%) patients received valemetostat 150 mg per day, 74 (82%) received 200 mg per day, seven received 250 mg per day, and two received 300 mg per day. Median follow-up was 7·4 months (IQR 3·4–17·6). All patients had at least one treatment-emergent adverse event; the most common treatment-emergent adverse events of any grade were decreased platelet count (52 [58%] of 90 patients), dysgeusia (45 [50%]), and anaemia (38 [42%]). The most common grade 3–4 adverse events were decreased neutrophil count (21 [","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142541565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA-PET research: addressing challenges and prospects","authors":"Dan Shan","doi":"10.1016/s1470-2045(24)00447-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00447-9","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"126 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer","authors":"Xiaoling Xu, Lisha Ye, Jinpeng Shi, Huihui Li, Yong Fang","doi":"10.1016/s1470-2045(24)00520-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00520-5","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer","authors":"Sarah Bowen Jones, Saskia Cooke, José Belderbos, Corinne Faivre-Finn","doi":"10.1016/s1470-2045(24)00529-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00529-1","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Oncol 2024; 25: 1325–36","authors":"","doi":"10.1016/s1470-2045(24)00587-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00587-4","url":null,"abstract":"<em>Iliopoulos O, Iversen AB, Narayan V, et al. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.</em> Lancet Oncol <em>2024; <strong>25:</strong> 1325–36</em>—In this Article, the second sentence in the fifth paragraph of the Results section, should read “After initiating belzutifan treatment, one patient (2%) underwent two CNS-related surgeries (cyst drainage and haemangioblastoma removal for the same lesion), and one patient (2%) received local radiotherapy approximately 5 weeks after starting belzutifan treatment.” These corrections have been made to the online version as of Oct 28, 2024.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}